Materiality pending
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
- Travere Therapeutics reported a quarterly loss of $1.76 per share, missing estimates. - Revenues for the quarter ended March 2024 were $41.37 million, missing estimates by 2.70%. - Travere's stock has lost about 30.4% since the beginning of the year. - Estimate revisions trend for Travere is unfavorable, resulting in a Zacks Rank #5 (Strong Sell). - Medical - Biomedical and Genetics industry is in the top 32% of Zacks industries. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Research Analysis
- Travere Therapeutics reported a quarterly loss of $1.76 per share, missing estimates.
- Revenues for the quarter ended March 2024 were $41.37 million, missing estimates by 2.70%.
- Travere's stock has lost about 30.4% since the beginning of the year.
- Estimate revisions trend for Travere is unfavorable, resulting in a Zacks Rank #5 (Strong Sell).
- Medical - Biomedical and Genetics industry is in the top 32% of Zacks industries.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.